<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02004678</url>
  </required_header>
  <id_info>
    <org_study_id>DS1150-A-U101</org_study_id>
    <nct_id>NCT02004678</nct_id>
  </id_info>
  <brief_title>Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of DS-1150b in Healthy Subjects and Subjects With Type-2 Diabetes Mellitus</brief_title>
  <official_title>Phase I, Single-Blind, Placebo-Controlled, Randomized, Two-Part, Sequential, Single Ascending Dose Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of DS-1150b in Healthy Subjects and Subjects With Type-2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daiichi Sankyo, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Daiichi Sankyo, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      DS-1150b is being developed by Daiichi Sankyo for the treatment of Type 2 Diabetes Mellitus.&#xD;
      This is a Phase I, single-blind (subjects and principal investigator blinded, Sponsor&#xD;
      unblinded), placebo-controlled, randomized, 2-part, sequential, single ascending dose, single&#xD;
      center study to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of&#xD;
      single oral dose of DS-1150b in healthy subjects and subjects with Type 2 Diabetes Mellitus.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Actual">October 2013</completion_date>
  <primary_completion_date type="Actual">September 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>area under curve (AUC)</measure>
    <time_frame>24 days, Day -5 to Day 19</time_frame>
    <description>To assess the effect of single oral doses of DS-1150b on glucose excursion (incremental glucose AUC0-3h) after an OGTT in subjects with Type 2 Diabetes Mellitus.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>maximum plasma concentration (Cmax)</measure>
    <time_frame>24 days, Day -5 to Day 19</time_frame>
    <description>To assess the effect of single oral doses of DS-1150b on glucose excursion (incremental glucose AUC0-3h) after an OGTT in subjects with Type 2 Diabetes Mellitus.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>terminal elimination half-life (t1/2)</measure>
    <time_frame>24 days, Day -5 to Day 19</time_frame>
    <description>To assess the effect of single oral doses of DS-1150b on glucose excursion (incremental glucose AUC0-3h) after an OGTT in subjects with Type 2 Diabetes Mellitus.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>time to reach maximum plasma concentration (Tmax)</measure>
    <time_frame>24 days, Day -5 to Day 19</time_frame>
    <description>To assess the effect of single oral doses of DS-1150b on glucose excursion (incremental glucose AUC0-3h) after an OGTT in subjects with Type 2 Diabetes Mellitus.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>measure the effects on Insulin and C-peptide Levels</measure>
    <time_frame>24 days, Day -5 to Day 19</time_frame>
    <description>To assess the effects of single oral dose of DS-1150b on insulin and C-peptide levels in subjects with Type 2 Diabetes Mellitus.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of patients experiencing adverse events</measure>
    <time_frame>24 days, Day -5 to Day 19</time_frame>
    <description>To assess the safety and tolerability of single oral dose of DS-1150b in subjects with Type 2 diabetes mellitus.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>measure the effects on glucagon Levels</measure>
    <time_frame>24 days, Day -5 to Day 19</time_frame>
    <description>To assess the effects of single oral dose of DS-1150b on glucagon levels in subjects with Type 2 Diabetes Mellitus.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of patients experiencing laboratory adverse events</measure>
    <time_frame>24 days, Day -5 to Day 19</time_frame>
    <description>To assess the safety and tolerability of single oral dose of DS-1150b in subjects with Type 2 diabetes mellitus.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Cohort 1, 7.5 mg DS-1150b</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Dosing will occur over two periods. Subjects will receive either&#xD;
a dose of placebo in Period 1 followed by a single dose of 7.5 mg DS-1150b in Period 2; or&#xD;
a single dose of 7.5 mg DS-1150b in Period 1 followed by a dose of placebo in Period 2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2, 15 mg DS-1150b</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Dosing will occur over two periods. Subjects will receive either&#xD;
a dose of placebo in Period 1 followed by a single dose of 15 mg DS-1150b in Period 2; or&#xD;
a single dose of 15 mg DS-1150b in Period 1 followed by a dose of placebo in Period 2.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DS-1150b</intervention_name>
    <arm_group_label>Cohort 1, 7.5 mg DS-1150b</arm_group_label>
    <arm_group_label>Cohort 2, 15 mg DS-1150b</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Cohort 1, 7.5 mg DS-1150b</arm_group_label>
    <arm_group_label>Cohort 2, 15 mg DS-1150b</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        All Subjects:&#xD;
&#xD;
          -  All women must have a negative serum pregnancy test at screening and a negative urine&#xD;
             pregnancy test on Day -1. Women must be of non-childbearing potential, either:&#xD;
&#xD;
               -  Surgically sterile (ie, bilateral tubal ligation or removal of both ovaries&#xD;
                  and/or uterus at least 6 months prior to dose administration).&#xD;
&#xD;
               -  &lt;60 years of age and naturally postmenopausal (spontaneous cessation of menses)&#xD;
                  for at least 24 consecutive months prior to dose administration, with a follicle&#xD;
                  stimulating hormone (FSH) level at screening of&#xD;
&#xD;
                  ≥40 mIU/mL.&#xD;
&#xD;
               -  &gt;60 years of age and naturally postmenopausal (spontaneous cessation of menses)&#xD;
                  for at least 24 consecutive months prior to dose administration.&#xD;
&#xD;
          -  Male subjects have to agree to contraception (condom with spermicide) in addition to&#xD;
             having their female partner (if of child-bearing potential) use another form of&#xD;
             contraception (eg, an intrauterine device, diaphragm with spermicide, oral until 12&#xD;
             weeks following the last dose administration. In addition, the male subjects must not&#xD;
             donate sperm after the study for a period of 12 weeks.&#xD;
&#xD;
          -  Subjects must give written informed consent to participate in the study prior to&#xD;
             screening.&#xD;
&#xD;
          -  Subjects must be in good health as determined by screening medical history, physical&#xD;
             examination findings, vital signs measurement, ECGs, serum chemistry, hematology,&#xD;
             virology (ie, HIV, HBV, and HCV at screening only), and urinalysis performed at&#xD;
             screening and on Day -1.&#xD;
&#xD;
          -  Subjects must agree to abstain from grapefruit/grapefruit juice and Seville oranges&#xD;
             from 10 days before the first dose and throughout the study.&#xD;
&#xD;
          -  All subjects must have a negative fecal occult blood test.&#xD;
&#xD;
        Part B (Type 2 Diabetes Mellitus):&#xD;
&#xD;
          -  Men and women who are not of childbearing potential, 18 years to 60 years of age,&#xD;
             inclusive.&#xD;
&#xD;
          -  A BMI of 25 kg/m2 to 38 kg/m2, inclusive.&#xD;
&#xD;
          -  Diagnosis of Type 2 DM for a minimum of 3 months prior to first dose.&#xD;
&#xD;
          -  Subjects should be either:&#xD;
&#xD;
               -  On metformin alone with a hemoglobin A1c (HBA1c) value between 7% to 9.5%,&#xD;
                  inclusive.&#xD;
&#xD;
               -  Treatment naïve or treatment free from any antidiabetic treatment for at least 3&#xD;
                  months prior to screening with a HBA1c value between 7% to 10%, inclusive.&#xD;
&#xD;
          -  Subjects with fasting plasma glucose ≥100 mg/dL and ≤250 mg/dL, for screening and on&#xD;
             Day -1.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        All Subjects:&#xD;
&#xD;
          -  History of gastrointestinal ulcer or erosion, or rhabdomyolysis within 6 months of&#xD;
             dose administration.&#xD;
&#xD;
          -  Subjects with laboratory results outside the normal range, if considered clinically&#xD;
             significant by the Investigator.&#xD;
&#xD;
          -  Subjects with serum K above the ULN of the clinical laboratory's reference range at&#xD;
             screening and on Day -1.&#xD;
&#xD;
          -  Subjects with CPK above the ULN at screening and on Day -1.&#xD;
&#xD;
          -  Subjects with lactate above the ULN at screening and on Day -1.&#xD;
&#xD;
          -  Subjects with QTcF interval duration &gt;450 msec, obtained as an average from the 3 ECG&#xD;
             recorder's measurements on the triplicate screening ECGs (3 ECGs in close succession&#xD;
             at least 1 min apart) taken after at least 10 minutes of quiet rest in supine&#xD;
             position.&#xD;
&#xD;
          -  Subjects with abnormal waveform morphology on any of the ECGs at the screening and on&#xD;
             Day -1 that would preclude accurate measurement of the QT interval duration.&#xD;
&#xD;
          -  History of any serious disorder, including cardiovascular, hematologic, pulmonary,&#xD;
             hepatic, renal, gastrointestinal, skeletal, connective tissue disease, uncontrolled&#xD;
             endocrine/metabolic other than subjects with Type 2 DM in Part B, oncologic (within&#xD;
             the last 5 years), neurologic, and psychiatric diseases, or any disorder that may&#xD;
             prevent the successful completion of the study.&#xD;
&#xD;
          -  Subjects who have had physical trauma, surgery or a significant illness within 4 weeks&#xD;
             prior to the first dose.&#xD;
&#xD;
          -  Donated or lost &gt;500 mL of blood or plasma within 3 months prior to the first dose on&#xD;
             Day 1.&#xD;
&#xD;
          -  Participated in a clinical study involving administration of an investigational drug&#xD;
             (new chemical entity), or a marked drug within the 30 days prior to administration of&#xD;
             the first dose.&#xD;
&#xD;
        Part B (Type 2 Diabetes Mellitus)&#xD;
&#xD;
          -  History of Type 1 diabetes and/or history of acute or chronic metabolic acidosis,&#xD;
             including diabetic ketoacidosis.&#xD;
&#xD;
          -  History of severe microvascular or macrovascular complications of Type 2 DM, including&#xD;
             proliferative retinopathy, macroalbuminuria, peripheral neuropathy, ischemic heart&#xD;
             disease, stroke, and peripheral vascular disease.&#xD;
&#xD;
          -  History of diabetic neuropathy.&#xD;
&#xD;
          -  Need for any concomitant medication that is moderate or strong CYP inhibitors&#xD;
             including CYP3A4, CYP2D6, CYP2C9, and CYP2C19, or P-gp inhibitor. Need for other&#xD;
             antidiabetic drugs except for metformin. Other common concomitant medications in&#xD;
             diabetic patients may be allowed (eg, aspirin and thyroid hormones) upon agreement&#xD;
             between the Sponsor and the PI.&#xD;
&#xD;
          -  Subjects with liver function of ALT and AST above 1.25 × ULN, or total bilirubin above&#xD;
             ULN at screening and on Day -1.&#xD;
&#xD;
          -  Moderate or severe renal dysfunction, defined as eGFR (using MDRD equation) &lt;60&#xD;
             mL/min.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Clinical Pharmacology of Miami, Inc.</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <study_first_submitted>October 25, 2013</study_first_submitted>
  <study_first_submitted_qc>December 4, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 9, 2013</study_first_posted>
  <last_update_submitted>December 20, 2018</last_update_submitted>
  <last_update_submitted_qc>December 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">December 24, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>De-identified individual participant data (IPD) and applicable supporting clinical trial documents may be available upon request at https://vivli.org/. In cases where clinical trial data and supporting documents are provided pursuant to our company policies and procedures, Daiichi Sankyo will continue to protect the privacy of our clinical trial participants. Details on data sharing criteria and the procedure for requesting access can be found at this web address: https://vivli.org/ourmember/daiichi-sankyo/</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>Studies for which the medicine and indication have received European Union (EU) and United States (US), and/or Japan (JP) marketing approval on or after 01 January 2014 or by the US or EU or JP Health Authorities when regulatory submissions in all regions are not planned and after the primary study results have been accepted for publication.</ipd_time_frame>
    <ipd_access_criteria>Formal request from qualified scientific and medical researchers on IPD and clinical study documents from clinical trials supporting products submitted and licensed in the United States, the European Union and/or Japan from 01 January 2014 and beyond for the purpose of conducting legitimate research. This must be consistent with the principle of safeguarding study participants' privacy and consistent with provision of informed consent.</ipd_access_criteria>
    <ipd_url>https://vivli.org/ourmember/daiichi-sankyo/</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

